59
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Transplantation provides superior survival high risk myeloid malignancies in older patients

ORCID Icon, , , &
Pages 2494-2498 | Received 28 Feb 2022, Accepted 04 May 2022, Published online: 19 May 2022
 

Disclosure statement

D.W., J.B., and S.N. have no relevant COI regarding this manuscript. E.W. UMOEN: Regional Oncology Pharmacy Conference: Paid Speaking Honorarium for lecture on the History of AML and new treatment updates. Currently Medical Director at Syros Pharmaceuticals and has stocks of the company. C.U. Honoria from blueprint for being in speaker bureau.

Figure 1. Disease-free survival in patients with MDS (A, reported by Nakamura et al. [Citation3]) and patients with AML (B, reported by Ustun et al. [Citation5]) is superior after allogeneic hematopoietic cell transplantation compared with no transplantation.

Figure 1. Disease-free survival in patients with MDS (A, reported by Nakamura et al. [Citation3]) and patients with AML (B, reported by Ustun et al. [Citation5]) is superior after allogeneic hematopoietic cell transplantation compared with no transplantation.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.